What is Calliditas Therapeutics AB (publ) (CALTX.ST)?

Calliditas Therapeutics AB (publ) (CALTX.ST) is a stock in the Healthcare sector, Biotechnology industry. View full analysis on Stocks360.

Calliditas Therapeutics AB (publ) (CALTX.ST)

Stock analysis · STO · Healthcare · Biotechnology

Market Cap

N/A

PE (TTM)

N/A

EPS (TTM)

N/A

Dividend Yield

N/A

Beta

1.46

Day Range

N/A

52-wk Range

N/A

Avg Volume

N/A

Volume

N/A

Calliditas Therapeutics AB (publ) (CALTX.ST) is a publicly traded company in the Healthcare sector. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

Earnings

Most Recent

Aug 13, 2024

EPS $-0.88 vs est. $-0.30

Missed by $0.58

Proprietary Signals

Signal snapshot temporarily unavailable.

About Calliditas Therapeutics AB (publ)

Calliditas Therapeutics AB is a clinical-stage biopharmaceutical company, established in Stockholm, Sweden in 2004. Its core business is to discover, develop, and commercialize pharmaceutical treatments for rare diseases, initially concentrating on conditions affecting the kidneys and liver. The company's portfolio features Nefecon, an oral budesonide immunosuppressant designed to treat immunoglobulin A nephropathy, an autoimmune renal disease. A leading candidate, Setanaxib, a NOX inhibitor, is currently in Phase 2b/3 trials for primary biliary cholangitis, and Phase 2 trials for squamous cell carcinoma of the head and neck, idiopathic pulmonary fibrosis, and type 1 diabetic kidney disease. Additionally, Calliditas develops Budenofalk 3 mg oral capsules for the management of autoimmune hepatitis.